Cargando…
Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy
Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune sti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996593/ https://www.ncbi.nlm.nih.gov/pubmed/33668932 http://dx.doi.org/10.3390/cells10030492 |
_version_ | 1783670138982105088 |
---|---|
author | Korbelik, Mladen Hode, Tomas Lam, Samuel S. K. Chen, Wei R. |
author_facet | Korbelik, Mladen Hode, Tomas Lam, Samuel S. K. Chen, Wei R. |
author_sort | Korbelik, Mladen |
collection | PubMed |
description | Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO). |
format | Online Article Text |
id | pubmed-7996593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79965932021-03-27 Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy Korbelik, Mladen Hode, Tomas Lam, Samuel S. K. Chen, Wei R. Cells Review Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO). MDPI 2021-02-25 /pmc/articles/PMC7996593/ /pubmed/33668932 http://dx.doi.org/10.3390/cells10030492 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Korbelik, Mladen Hode, Tomas Lam, Samuel S. K. Chen, Wei R. Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title | Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title_full | Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title_fullStr | Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title_full_unstemmed | Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title_short | Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy |
title_sort | novel immune stimulant amplifies direct tumoricidal effect of cancer ablation therapies and their systemic antitumor immune efficacy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996593/ https://www.ncbi.nlm.nih.gov/pubmed/33668932 http://dx.doi.org/10.3390/cells10030492 |
work_keys_str_mv | AT korbelikmladen novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy AT hodetomas novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy AT lamsamuelsk novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy AT chenweir novelimmunestimulantamplifiesdirecttumoricidaleffectofcancerablationtherapiesandtheirsystemicantitumorimmuneefficacy |